Amicus Therapeutics, Inc.

1 Cedar Brook Drive
Cranbury
New Jersey
08512
United States

About Amicus Therapeutics, Inc.

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).

The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.

321 articles with Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. Files for $86.25 Million IPO

4/2/2007
Amicus Therapeutics, Inc. Presents Positive Results From Phase 1 Clinical Studies of Plicera(TM) for Gaucher Disease

3/21/2007
Amicus Therapeutics, Inc. Presents Preclinical Data from Studies of Plicera(TM) for Gaucher Disease

3/20/2007
Amicus Therapeutics, Inc. Presents Data From Preclinical and Phase 1 Studies of Amigal(TM) for Fabry Disease

3/19/2007
Amicus Therapeutics, Inc. Completes Phase 2 Enrollment of Amigal(TM) for Fabry Disease

3/16/2007
Amicus Therapeutics, Inc. Announces Return of John F. Crowley as President and Chief Executive Officer

3/5/2007
Amicus Therapeutics, Inc. Receives Grant From Michael J. Fox Foundation For Parkinson's Research

1/24/2007
Amicus Therapeutics, Inc. Commences Phase 1 Clinical Trials For AT2220 For Pompe Disease

12/14/2006
Amicus Therapeutics, Inc. Appoints Chief Financial Officer

10/2/2006
Studies Published In PNAS On The Mechanism Of Amicus Therapeutics, Inc.'s Experimental Treatment For Gaucher Disease

9/20/2006
Amicus Therapeutics, Inc. Raises $60 Million Series D Financing Company Also Makes Two Key Executive Appointments

9/14/2006
Amicus Therapeutics, Inc. Pulls $86M IPO Citing Market Conditions

8/4/2006
Amicus Therapeutics, Inc. Adds Glenn P. Sblendorio To Board Of Directors

7/5/2006
Amicus Therapeutics, Inc. Files For $86.25 Million IPO

5/17/2006
Amicus Therapeutics, Inc. Files Investigational New Drug Application For AT2101 For Gaucher Disease

4/27/2006
European Regulatory Committee Recommends Orphan Medicinal Product Designation For Amicus Therapeutics, Inc.' Amigal(TM) For Fabry Disease

4/11/2006
Amicus Therapeutics, Inc. Appoints Pharmaceutical Veteran Donald Hayden, Jr. Executive Chairman Of Its Board Of Directors

3/30/2006
Amicus Therapeutics, Inc. To Present At The BioCentury/BioCentury Publications Inc. 'Future Leaders In The Biotech Industry' Conference

3/27/2006
Amicus Therapeutics, Inc.' AT2101 Granted Orphan Drug Designation For The Treatment Of Gaucher Disease

2/15/2006
Amicus Therapeutics, Inc. Appoints David J. Lockhart Chief Scientific Officer

1/6/2006

First
Previous
16
17
Next
Last